&lt;p&gt;Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome&lt;/p&gt;

Chirchiglia, Domenico; Caldarola, Pasquale; Marotta, Rosa; Gallelli, Luca

doi:10.2147/imcrj.s194403

Cited by 5 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 51 Other antioxidant agents such as melatonin 58 and Alpha‐lipoic acid (ALA) have examined, the last of them having the highest number of clinical trial studies. The four case reports and case series studies have shown the therapeutic effects of antioxidant agents, methylene blue, 61 Chamomile, 57 ultramicronized palmitoylethanolamide 59 in secondary BMS patients (Table 4 ).…”

Section: Discussionmentioning

confidence: 99%

Micronutrients status as a contributing factor in secondary burning mouth syndrome: A review of the literature

Gholizadeh,

Sheykhbahaei

2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsPatients with burning mouth syndrome (BMS) experience an annoying feeling without clinical evidence of any mucosal lesion. Deficiency or excess of micronutrients is a common feature in secondary BMS. There is limited knowledge among oral healthcare providers regarding the significance of micronutrients in oral health, so the current review focuses on the critical role of these elements in oral health implications as secondary BMS.MethodsFor the data collection, the authors searched for key terms without time limitation (1900–2021) in databases comprised of PubMed, Google Scholar, Scopus, Web of Science (SCI), and Embase.ResultsThe total number of matched articles with inclusion criteria involved in this review article was 59 original articles. Among these, 20 randomized clinical trials (RCT), 31 case‐control or Crossectional, and 8 case reports/series are reviewed in this review article.ConclusionOne of the important etiological factors in patients with secondary BMS is micronutrient imbalance. The iron, zinc, vitamin B family, vitamin D deficiency and increased levels of homocysteine and oxidant agents were examined in secondary BMS patients. In addition, oral medicine specialists must consider the possible toxic effects of some elements in restorations and dental prostheses. Further studies, such as RCTs in the future, are recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Micronutrients status as a contributing factor in secondary burning mouth syndrome: A review of the literature

Gholizadeh,

Sheykhbahaei

2024

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…On the clinical side, micro-PEA (i.e., micronized, ultramicronized or co-micronized PEA) has been orally administered as a dietary food for special medical purposes to human patients, either singly [ 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 ] or in combination with (i.e., add-on dietary intervention to) opioids, gabapentenoids or NSAIDs [ 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 ], as well as antioxidant compounds (e.g., luteolin, quercetin, polydatin) [ 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , …”

Section: Clinical Evidence For Micro-pea Dietary Supplementation In Pain Reliefmentioning

confidence: 99%

Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?

Rocca

Gamba²

2021

Animals

View full text Add to dashboard Cite

The management of chronic pain is an integral challenge of small animal veterinary practitioners. Multiple pharmacological agents are usually employed to treat maladaptive pain including opiates, non-steroidal anti-inflammatory drugs, anticonvulsants, antidepressants, and others. In order to limit adverse effects and tolerance development, they are often combined with non-pharmacologic measures such as acupuncture and dietary interventions. Accumulating evidence suggests that non-neuronal cells such as mast cells and microglia play active roles in the pathogenesis of maladaptive pain. Accordingly, these cells are currently viewed as potential new targets for managing chronic pain. Palmitoylethanolamide is an endocannabinoid-like compound found in several food sources and considered a body’s own analgesic. The receptor-dependent control of non-neuronal cells mediates the pain-relieving effect of palmitoylethanolamide. Accumulating evidence shows the anti-hyperalgesic effect of supplemented palmitoylethanolamide, especially in the micronized and co-micronized formulations (i.e., micro-palmitoylethanolamide), which allow for higher bioavailability. In the present paper, the role of non-neuronal cells in pain signaling is discussed and a large number of studies on the effect of palmitoylethanolamide in inflammatory and neuropathic chronic pain are reviewed. Overall, available evidence suggests that there is place for micro-palmitoylethanolamide in the dietary management of chronic pain in dogs and cats.

show abstract

“…To reduce the development of ADRs, which could be also related to the dosage and the long duration of treatment, a nonpharmacological treatment has been suggested. Nutrients are commonly used in patients with pain, e.g., Acetyl-L-carnitine [14][15][16][17][18][19][20], palmitoylethanolamide (PEA) [21][22][23][24][25][26][27], and alpha-lipoic acid [28][29][30][31][32][33][34][35].…”

Section: Introductionmentioning

confidence: 99%

The Safety of Drug Treatment in Patients with Neuropathic Pain: Data from Ambulatory Care in a Real-Life Setting

Vocca,

Rania,

Siniscalchi

et al. 2023

Reports

Self Cite

View full text Add to dashboard Cite

Introduction: Drug treatment can be related to the development of adverse drug reactions (ADRs). Aim: In this paper, we evaluated ADRs in patients admitted to the Ambulatory of Pain Medicine of the University Hospital Renato Dulbecco in Catanzaro. Methods: We conducted a prospective analysis between 1 February 2021 and 20 July 2023 on patients with neuropathic pain referred to the Ambulatory of Pain Medicine of “Renato Dulbecco” University Hospital in Catanzaro (Calabria, Italy). Patients aged >18 years with clinical signs of neurologic pain and a score upon completing the Douleur Neuropathique en 4 Questions (DN4) questionnaire of ≥4 were included. The association between drugs and ADR or between drugs and drug–drug-interactions (DDIs) was evaluated using Naranjo’s probability scale and Drug Interaction Probability Scale (DIPS), respectively. Results: During the study period, we analyzed 2370 patients referred to the ambulatory of pain medicine. After the evaluation of inclusion and exclusion criteria, 33.5% of patients were enrolled. All patients presented at least one comorbidity and daily used a mean of five drugs (range 3–11). Using the Naranjo score, the development of ADRs was documented in 112 patients (score 6). Using parametric and non-parametric statistical analysis, we failed to report an association between ADR and dosage or ADR and patient characteristics. Conclusion: Our results show the development of ADRs in 18% of patients with neuropathic pain. This low percentage of drug interaction could be a limitation in real life because it is probably due to the site of the study and the appropriate prescription of drugs. Therefore, it shows that it is necessary to motivate healthcare to pay attention to the prescription of drugs in poly-treated patients to reduce the risk of ADRs.

show abstract

<p>Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome</p>

Cited by 5 publications

References 13 publications

Micronutrients status as a contributing factor in secondary burning mouth syndrome: A review of the literature

Micronutrients status as a contributing factor in secondary burning mouth syndrome: A review of the literature

Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?

The Safety of Drug Treatment in Patients with Neuropathic Pain: Data from Ambulatory Care in a Real-Life Setting

Contact Info

Product

Resources

About